Virtus Investment Advisers’s Allogene Therapeutics ALLO Stock Holding History

Virtus Investment Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$358K	Sell	172,209 -8,379	-5%	-$18.4K	0.08%	341
2026 Q1	$441K	Buy	180,588 +4,410	+3%	+$8.84K	0.12%	233
2025 Q4	$241K	Buy	176,178 +94,902	+117%	+$125K	0.07%	344
2025 Q3	$101K	Buy	81,276 +14,110	+21%	+$16.8K	0.03%	425
2025 Q2	$75.9K	Sell	67,166 -14,104	-17%	-$18.7K	0.03%	429
2025 Q1	$119K	Buy	+81,270	New	+$153K	0.03%	394

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Virtus Investment Advisers's ALLO Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Allogene Therapeutics (ALLO) stake by 4.6% in Q2 2026, selling an estimated $18.4K and leaving 172,209 shares worth $358K. The position accounts for 0.08% of the portfolio, ranked #341.

Virtus Investment Advisers first reported a position in ALLO in Q1 2025 and has held it in 6 quarters since. The position peaked at $441K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Virtus Investment Advisers held 172,209 shares of Allogene Therapeutics worth $358K as of Q2 2026.
Virtus Investment Advisers sold 8,379 Allogene Therapeutics shares in Q2 2026, an estimated $18.4K.
Allogene Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #341 holding.
Virtus Investment Advisers first reported a position in Allogene Therapeutics in Q1 2025 and has held it in 6 quarters since.
Virtus Investment Advisers's Allogene Therapeutics position peaked at $441K in Q1 2026.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.